Finnrick Test Reveals 78% of Peptide Brands Fail Purity & Potency Standards
Title: Finnrick Test Reveals 78% of Peptide Brands Fail Purity & Potency Standards Abstract: The Finnrick Test, analyzing 200+ commercial peptide products, reveals that 78% of brands fail to meet declared purity and potency standards, with actual purity averaging 72% vs. claimed 98%. This systemic quality gap underscores critical market trends: rising demand for GLP-1 agonists and research-grade peptides, yet widespread adulteration and mislabeling. Brands with ISO 9001 and third-party COA certifications (e.g., verified HPLC/MS reports) demonstrate superior consistency (purity >95%). Key selection criteria include batch-specific certificates, cold-chain logistics compliance, and supplier transparency. The findings highlight urgent industry needs for standardized testing and regulatory oversight to ensure therapeutic efficacy and research reproducibility.